|Articles|October 1, 2001
VISX, Medjet share research on waterjet, might unite
Santa Clara, CA-VISX Inc. will pay Medjet Inc. to pursue new ophthalmictechnologies and products in exchange for a 1-year option to acquire alloutstanding Medjet common stock in a merger transaction that would pay $2cash per share.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts
2
EURETINA 2026: Real-world evidence on retinal biosimilars
3
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
4
FAQ: What clinicians need to know about OCU410 phase 2 ArMaDa results
5















